{"pmid":32298981,"title":"Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations.","text":["Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations.","BACKGROUND AND AIMS: High prevalence of diabetes makes it an important comorbidity in patients with COVID-19. We sought to review and analyze the data regarding the association between diabetes and COVID-19, pathophysiology of the disease in diabetes and management of patients with diabetes who develop COVID-19 infection. METHODS: PubMed database and Google Scholar were searched using the key terms 'COVID-19', 'SARS-CoV-2', 'diabetes', 'antidiabetic therapy' up to April 2, 2020. Full texts of the retrieved articles were accessed. RESULTS: There is evidence of increased incidence and severity of COVID-19 in patients with diabetes. COVID-19 could have effect on the pathophysiology of diabetes. Blood glucose control is important not only for patients who are infected with COVID-19, but also for those without the disease. Innovations like telemedicine are useful to treat patients with diabetes in today's times.","Diabetes Metab Syndr","Singh, Awadhesh Kumar","Gupta, Ritesh","Ghosh, Amerta","Misra, Anoop","32298981"],"abstract":["BACKGROUND AND AIMS: High prevalence of diabetes makes it an important comorbidity in patients with COVID-19. We sought to review and analyze the data regarding the association between diabetes and COVID-19, pathophysiology of the disease in diabetes and management of patients with diabetes who develop COVID-19 infection. METHODS: PubMed database and Google Scholar were searched using the key terms 'COVID-19', 'SARS-CoV-2', 'diabetes', 'antidiabetic therapy' up to April 2, 2020. Full texts of the retrieved articles were accessed. RESULTS: There is evidence of increased incidence and severity of COVID-19 in patients with diabetes. COVID-19 could have effect on the pathophysiology of diabetes. Blood glucose control is important not only for patients who are infected with COVID-19, but also for those without the disease. Innovations like telemedicine are useful to treat patients with diabetes in today's times."],"journal":"Diabetes Metab Syndr","authors":["Singh, Awadhesh Kumar","Gupta, Ritesh","Ghosh, Amerta","Misra, Anoop"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32298981","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.dsx.2020.04.004","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664266651178106880,"score":8.233237,"similar":[{"pmid":32283497,"pmcid":"PMC7129346","title":"Telemedicine for diabetes care in India during COVID19 pandemic and national lockdown period: Guidelines for physicians.","text":["Telemedicine for diabetes care in India during COVID19 pandemic and national lockdown period: Guidelines for physicians.","BACKGROUND AND AIMS: In view of restrictions on mobility of patients because of COVID-19 pandemic, face-to-face consultations are difficult. We sought to study the feasibility of telemedicine in this scenario. METHODS: PubMed and Google Scholar search engines were searched using the key terms 'telemedicine', 'diabetes', 'COVID-19 up to 31(st) March 2020. In addition, existing guidelines including those by Ministry of Health and Family Welfare (MOHFW), Government of India, were accessed. RESULTS: We discuss evidence and general guidelines regarding role of telemedicine in patients with diabetes along with its utility and limitations. CONCLUSIONS: Telemedicine is a useful tool for managing patients of diabetes during this lockdown period. However, there is limited data and further research is required.","Diabetes Metab Syndr","Ghosh, Amerta","Gupta, Ritesh","Misra, Anoop","32283497"],"abstract":["BACKGROUND AND AIMS: In view of restrictions on mobility of patients because of COVID-19 pandemic, face-to-face consultations are difficult. We sought to study the feasibility of telemedicine in this scenario. METHODS: PubMed and Google Scholar search engines were searched using the key terms 'telemedicine', 'diabetes', 'COVID-19 up to 31(st) March 2020. In addition, existing guidelines including those by Ministry of Health and Family Welfare (MOHFW), Government of India, were accessed. RESULTS: We discuss evidence and general guidelines regarding role of telemedicine in patients with diabetes along with its utility and limitations. CONCLUSIONS: Telemedicine is a useful tool for managing patients of diabetes during this lockdown period. However, there is limited data and further research is required."],"journal":"Diabetes Metab Syndr","authors":["Ghosh, Amerta","Gupta, Ritesh","Misra, Anoop"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32283497","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.dsx.2020.04.001","source":"PubMed","topics":["Prevention"],"weight":1,"locations":["India","India"],"countries":["India"],"countries_codes":["IND|India"],"_version_":1664182200870895617,"score":471.32654},{"pmid":32278764,"title":"COVID-19 and Diabetes: Knowledge in Progress.","text":["COVID-19 and Diabetes: Knowledge in Progress.","AIMS: We aimed to briefly review the general characteristics of the novel coronavirus (SARS-CoV-2) and provide a better understanding of the coronavirus disease (COVID-19) in people with diabetes, and its management. METHODS: We searched for articles in PubMed and Google Scholar databases till 02 April 2020, with the following keywords: \"SARS-CoV-2\", \"COVID-19\", \"infection\", \"pathogenesis\", \"incubation period\", \"transmission\", \"clinical features\", \"diagnosis\", \"treatment\", \"diabetes\", with interposition of the Boolean operator \"AND\". RESULTS: The clinical spectrum of COVID-19 is heterogeneous, ranging from mild flu-like symptoms to acute respiratory distress syndrome, multiple organ failure and death. Older age, diabetes and other comorbidities are reported as significant predictors of morbidity and mortality. Chronic inflammation, increased coagulation activity, immune response impairment, and potential direct pancreatic damage by SARS-CoV-2 might be among the underlying mechanisms of the association between diabetes and COVID-19. No conclusive evidence exists to support the discontinuation of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers because of COVID-19 in people with diabetes. Caution should be taken to potential hypoglycemic events with the use of chloroquine in these subjects. Patient tailored therapeutic strategies, rigorous glucose monitoring and careful consideration of drug interactions might reduce adverse outcomes. CONCLUSIONS: Suggestions are made on the possible pathological mechanisms of the relationship between diabetes and COVID-19, and its management. No definite conclusions can be made based on current limited evidence. Further research regarding this relationship and its clinical management is warranted.","Diabetes Res Clin Pract","Hussain, Akhtar","Bhowmik, Bishwajit","Cristina do Vale Moreira, Nayla","32278764"],"abstract":["AIMS: We aimed to briefly review the general characteristics of the novel coronavirus (SARS-CoV-2) and provide a better understanding of the coronavirus disease (COVID-19) in people with diabetes, and its management. METHODS: We searched for articles in PubMed and Google Scholar databases till 02 April 2020, with the following keywords: \"SARS-CoV-2\", \"COVID-19\", \"infection\", \"pathogenesis\", \"incubation period\", \"transmission\", \"clinical features\", \"diagnosis\", \"treatment\", \"diabetes\", with interposition of the Boolean operator \"AND\". RESULTS: The clinical spectrum of COVID-19 is heterogeneous, ranging from mild flu-like symptoms to acute respiratory distress syndrome, multiple organ failure and death. Older age, diabetes and other comorbidities are reported as significant predictors of morbidity and mortality. Chronic inflammation, increased coagulation activity, immune response impairment, and potential direct pancreatic damage by SARS-CoV-2 might be among the underlying mechanisms of the association between diabetes and COVID-19. No conclusive evidence exists to support the discontinuation of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers because of COVID-19 in people with diabetes. Caution should be taken to potential hypoglycemic events with the use of chloroquine in these subjects. Patient tailored therapeutic strategies, rigorous glucose monitoring and careful consideration of drug interactions might reduce adverse outcomes. CONCLUSIONS: Suggestions are made on the possible pathological mechanisms of the relationship between diabetes and COVID-19, and its management. No definite conclusions can be made based on current limited evidence. Further research regarding this relationship and its clinical management is warranted."],"journal":"Diabetes Res Clin Pract","authors":["Hussain, Akhtar","Bhowmik, Bishwajit","Cristina do Vale Moreira, Nayla"],"date":"2020-04-13T11:00:00Z","year":2020,"_id":"32278764","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.diabres.2020.108142","keywords":["COVID-19","SARS-CoV-2","clinical management","diabetes","pathogenesis"],"source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"locations":["Boolean","Progress"],"_version_":1663890921964437506,"score":442.60217},{"pmid":32294179,"title":"Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications.","text":["Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications.","Individuals with diabetes are at increased risk for bacterial, mycotic, parasitic and viral infections. The severe acute respiratory syndrome (SARS)-CoV2 (also referred to as COVID-19) coronavirus pandemic highlights the importance of understanding shared disease pathophysiology potentially informing therapeutic choices in individuals with Type 2 diabetes (T2D). Two coronavirus receptor proteins, Angiotensin Converting Enzyme 2 (ACE2) and Dipeptidyl Peptidase-4 (DPP4) are also established transducers of metabolic signals and pathways regulating inflammation, renal and cardiovascular physiology, and glucose homeostasis. Moreover, glucose-lowering agents such as the DPP4 inhibitors, widely used in subjects with T2D, are known to modify the biological activities of multiple immunomodulatory substrates. Here we review the basic and clinical science spanning the intersections of diabetes, coronavirus infections, ACE2, and DPP4 biology, highlighting clinical relevance and evolving areas of uncertainty underlying the pathophysiology and treatment of T2D in the context of coronavirus infection.","Endocr Rev","Drucker, Daniel J","32294179"],"abstract":["Individuals with diabetes are at increased risk for bacterial, mycotic, parasitic and viral infections. The severe acute respiratory syndrome (SARS)-CoV2 (also referred to as COVID-19) coronavirus pandemic highlights the importance of understanding shared disease pathophysiology potentially informing therapeutic choices in individuals with Type 2 diabetes (T2D). Two coronavirus receptor proteins, Angiotensin Converting Enzyme 2 (ACE2) and Dipeptidyl Peptidase-4 (DPP4) are also established transducers of metabolic signals and pathways regulating inflammation, renal and cardiovascular physiology, and glucose homeostasis. Moreover, glucose-lowering agents such as the DPP4 inhibitors, widely used in subjects with T2D, are known to modify the biological activities of multiple immunomodulatory substrates. Here we review the basic and clinical science spanning the intersections of diabetes, coronavirus infections, ACE2, and DPP4 biology, highlighting clinical relevance and evolving areas of uncertainty underlying the pathophysiology and treatment of T2D in the context of coronavirus infection."],"journal":"Endocr Rev","authors":["Drucker, Daniel J"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32294179","week":"202016|Apr 13 - Apr 19","doi":"10.1210/endrev/bnaa011","keywords":["Angiotensin Converting Enzyme 2","Diabetes","Dipeptidyl Peptidase-4","Obesity","Receptor","Virus"],"source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1664266295765368832,"score":381.441},{"pmid":32302499,"title":"Managing New-Onset Type 1 Diabetes During the COVID-19 Pandemic: Challenges and Opportunities.","text":["Managing New-Onset Type 1 Diabetes During the COVID-19 Pandemic: Challenges and Opportunities.","Background: The current COVID-19 pandemic provides an incentive to expand considerably the use of telemedicine for high-risk patients with diabetes, and especially for the management of type 1 diabetes (T1D). Telemedicine and digital medicine also offer critically important approaches to improve access, efficacy, efficiency, and cost-effectiveness of medical care for people with diabetes. Methods: Two case reports are presented where telemedicine was used effectively and safely after day 1 in person patient education. These aspects of the management of new-onset T1D patients (adult and pediatric) included ongoing diabetes education of the patient and family digitally. The patients used continuous glucose monitoring with commercially available analysis software (Dexcom Clarity and Glooko) to generate ambulatory glucose profiles and interpretive summary reports. The adult subject used multiple daily insulin injections; the pediatric patient used an insulin pump. The subjects were managed using a combination of e-mail, Internet via Zoom, and telephone calls. Results: These two cases show the feasibility and effectiveness of use of telemedicine in applications in which we had not used it previously: new-onset diabetes education and insulin dosage management. Conclusions: The present case reports illustrate how telemedicine can be used safely and effectively for new-onset T1D training and education for both pediatric and adult patients and their families. The COVID-19 pandemic has acutely stimulated the expansion of the use of telemedicine and digital medicine. We conclude that telemedicine is an effective approach for the management of patients with new-onset T1D.","Diabetes Technol Ther","Garg, Satish K","Rodbard, David","Hirsch, Irl B","Forlenza, Gregory P","32302499"],"abstract":["Background: The current COVID-19 pandemic provides an incentive to expand considerably the use of telemedicine for high-risk patients with diabetes, and especially for the management of type 1 diabetes (T1D). Telemedicine and digital medicine also offer critically important approaches to improve access, efficacy, efficiency, and cost-effectiveness of medical care for people with diabetes. Methods: Two case reports are presented where telemedicine was used effectively and safely after day 1 in person patient education. These aspects of the management of new-onset T1D patients (adult and pediatric) included ongoing diabetes education of the patient and family digitally. The patients used continuous glucose monitoring with commercially available analysis software (Dexcom Clarity and Glooko) to generate ambulatory glucose profiles and interpretive summary reports. The adult subject used multiple daily insulin injections; the pediatric patient used an insulin pump. The subjects were managed using a combination of e-mail, Internet via Zoom, and telephone calls. Results: These two cases show the feasibility and effectiveness of use of telemedicine in applications in which we had not used it previously: new-onset diabetes education and insulin dosage management. Conclusions: The present case reports illustrate how telemedicine can be used safely and effectively for new-onset T1D training and education for both pediatric and adult patients and their families. The COVID-19 pandemic has acutely stimulated the expansion of the use of telemedicine and digital medicine. We conclude that telemedicine is an effective approach for the management of patients with new-onset T1D."],"journal":"Diabetes Technol Ther","authors":["Garg, Satish K","Rodbard, David","Hirsch, Irl B","Forlenza, Gregory P"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32302499","week":"202016|Apr 13 - Apr 19","doi":"10.1089/dia.2020.0161","keywords":["cgm","covid-19","health economics","new-onset type 1 diabetes","telemedicine","virtual"],"source":"PubMed","topics":["Prevention","Treatment"],"weight":1,"_version_":1664357978727251968,"score":372.8918},{"pmid":32233013,"title":"Diabetes is a risk factor for the progression and prognosis of COVID-19.","text":["Diabetes is a risk factor for the progression and prognosis of COVID-19.","AIM: To figure out whether diabetes is a risk factor influencing the progression and prognosis of 2019 novel coronavirus disease (COVID-19). MATERIALS AND METHODS: A total of 174 consecutive patients confirmed with COVID-19 were studied. Demographic data, medical history, symptoms and signs, laboratory findings, chest computed tomography (CT) as well we treatment measures were collected and analyzed. RESULTS: We found that COVID-19 patients without other comorbidities but with diabetes (n=24) were at higher risk of severe pneumonia, release of tissue injury-related enzymes, excessive uncontrolled inflammation responses and hypercoagulable state associated with dysregulation of glucose metabolism. Furthermore, serum levels of inflammation related biomarkers such as IL-6, C-reactive protein, serum ferritine and coagulation index, D-dimer, were significantly higher (p< 0.01) in diabetic patients compared with those without, suggesting that patients with diabetes are more susceptible to an inflammatory storm eventually leading to rapid deterioration of COVID-19. CONCLUSIONS: Our data support the notion that diabetes should be considered as a risk factor for a rapid progression and bad prognosis of COVID-19. More intensive attention should be paid to patients with diabetes, in case of rapid deterioration. This article is protected by copyright. All rights reserved.","Diabetes Metab Res Rev","Guo, Weina","Li, Mingyue","Dong, Yalan","Zhou, Haifeng","Zhang, Zili","Tian, Chunxia","Qin, Renjie","Wang, Haijun","Shen, Yin","Du, Keye","Zhao, Lei","Fan, Heng","Luo, Shanshan","Hu, Desheng","32233013"],"abstract":["AIM: To figure out whether diabetes is a risk factor influencing the progression and prognosis of 2019 novel coronavirus disease (COVID-19). MATERIALS AND METHODS: A total of 174 consecutive patients confirmed with COVID-19 were studied. Demographic data, medical history, symptoms and signs, laboratory findings, chest computed tomography (CT) as well we treatment measures were collected and analyzed. RESULTS: We found that COVID-19 patients without other comorbidities but with diabetes (n=24) were at higher risk of severe pneumonia, release of tissue injury-related enzymes, excessive uncontrolled inflammation responses and hypercoagulable state associated with dysregulation of glucose metabolism. Furthermore, serum levels of inflammation related biomarkers such as IL-6, C-reactive protein, serum ferritine and coagulation index, D-dimer, were significantly higher (p< 0.01) in diabetic patients compared with those without, suggesting that patients with diabetes are more susceptible to an inflammatory storm eventually leading to rapid deterioration of COVID-19. CONCLUSIONS: Our data support the notion that diabetes should be considered as a risk factor for a rapid progression and bad prognosis of COVID-19. More intensive attention should be paid to patients with diabetes, in case of rapid deterioration. This article is protected by copyright. All rights reserved."],"journal":"Diabetes Metab Res Rev","authors":["Guo, Weina","Li, Mingyue","Dong, Yalan","Zhou, Haifeng","Zhang, Zili","Tian, Chunxia","Qin, Renjie","Wang, Haijun","Shen, Yin","Du, Keye","Zhao, Lei","Fan, Heng","Luo, Shanshan","Hu, Desheng"],"date":"2020-04-02T11:00:00Z","year":2020,"_id":"32233013","week":"202014|Mar 30 - Apr 05","doi":"10.1002/dmrr.3319","keywords":["COVID-19","Diabetes","prognosis"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"_version_":1663352135382728704,"score":357.08542}]}